Spartalizumab
PD-1 (CD279) | |
|---|---|
| Clinical data | |
| Other names | PDR001 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Spartalizumab (
INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma
.
This drug is being developed by
Phase III trials.[2]
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- PMID 31847708.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |